The Effect of Acipimox on GLP (Glucagon-like Peptide)-1 Secretion

University of Aarhus8 enrolled

Overview

Glucagon like peptide 1 is produced in enteroendocrine L cells in the small intestine stimulated by peroral food intake. GLP-1 induces insulin secretion, and analogues are used in the treatment of DM2 (type 2 diabetes mellitus). Recently it was found, that levels of GLP-1 are increased in response to acipimox. The hypothesis is that G protein coupled receptors on enteroendocrine L cells bind acipimox and thereby induce GLP-1 secretion. In a controlled, open, randomized experiment, eight healthy, overweight men will be studied on an intervention day, where they receive acipimox, and on a control day. The study day includes an OGTT (oral glucose tolerance test), blood samples before and after the OGTT and a biopsy from adipose tissue.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

BASIC_SCIENCE

Masking

NONE

Enrollment

Conditions

Diabetes Mellitus Type 2

Interventions

P.o. administration of 250 mg acipimox

Eligibility

Sex: MALEMin age: 20 YearsMax age: 50 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Adult men * Healthy * BMI 25-35 Exclusion Criteria: * Known DM2 * Receiving hypolipidemic drugs

Locations (1)

University Hospital of Aarhus

Aarhus, Denmark

Outcomes

Primary Outcomes

Levels of GLP-1 in plasma

Time frame: 9 months

Secondary Outcomes

Lipolytic activity in adipose tissue by measuring FFA (free fatty acid) levels

Time frame: 9 months

Insulin sensitivity by measuring blood glucose after an OGTT

Time frame: 5 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.